Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects

Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate and OATP1B1/1B3 inhibitor in vitro. A phase I drug-drug interaction (DDI) study ( = 15) was conducted in healthy subje...

Full description

Bibliographic Details

Published in:	The Journal of pharmacology and experimental therapeutics Vol. 378; no. 2; p. 87
Main Authors:	Sane, Rucha S, Cheung, Kit Wun Kathy, Cho, Eunpi, Liederer, Bianca M, Hanover, Justin, Malhi, Vikram, Plise, Emile, Wong, Susan, Musib, Luna
Format:	Journal Article
Language:	English
Published:	United States 01.08.2021
Subjects:	Adult Coproporphyrins - metabolism Cytochrome P-450 CYP3A - metabolism Drug Interactions Female Healthy Volunteers Humans Itraconazole - pharmacology Male Middle Aged Piperazines Pyrimidines - pharmacokinetics Pyrimidines - pharmacology Young Adult
ISSN:	1521-0103, 1521-0103
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!